Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2014

View Archived Issues

Preclinical and phase I clinical profile of Virobay's cathepsin S inhibitors for neuropathic pain

U.S. scientists disclose new compounds for drug-resistant tuberculosis

iTeos Therapeutics collaborates with Pfizer on IDO1 and TDO2 programs

Circassia reports results from phase IIb trial of Ragweed-SPIRE vaccine

Cureveda receives NIH grants for development of VEDA-1209

MLN-7243, a first-in-class ubiquitin-activating enzyme inhibitor as a cancer therapy

QLT discloses results from phase IIa trial of QLT-091001 in impaired dark adaptation

Novel biomarkers associated with obesity and obesity-related diseases

New phase I study evaluates Cornerstone's CPI-613 for B-cell NHL

Euroscreen successfully completes phase I study of ESN-364

Phase III data demonstrate equivalence in efficacy of etanercept biosimilar in RA

Zydus Cadila launches adalimumab biosimilar in India

Lilly and Incyte report topline results from phase III trial of baricitinib

ONO-8610539: a potent coagulation factor XIa inhibitor for the treatment of DVT

Novel HCV NS3/4A inhibitors disclosed by Beijing Xintianyu Technology Development

Jiangsu Simcere Pharmaceutical divulges novel BTK inhibitors

AT-001 given U.S. orphan drug designation for X-linked myotubular myopathy

4SC reports positive topline data from phase I trial of 4SC-205 in cancer patients

First-in-class PRMT5 inhibitor as a potential therapy for mantle cell lymphoma

Mast Therapeutics provides update on development plan for vepoloxamer

Dynavax and AstraZeneca to advance AZD-1419 to phase IIa for asthma

Brilacidin receives FDA QIDP designation

Merck & Co. to acquire Cubist Pharmaceuticals

Vaccinex's anti-SEMA4D antibody VX-15/2503 is well tolerated in patients with solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.